Evaluation Of A Fetal Sex Determination Test At 36-56 Days Gestation In Assisted Reproductive Technology (ART) Achieved Pregnancies
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Fetal Sex Determination
- Sponsor
- Sequenom, Inc.
- Enrollment
- 500
- Locations
- 3
- Primary Endpoint
- Develop a prenatal sex test using blood and/or urine samples from pregnant women.
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
Whole blood and urine samples will be collected from pregnant woman of gestational age 36-56 days as confirmed by artificial reproductive technology (ART). The samples will be used to develop a prenatal sex test using circulating cell free fetal DNA (ccffDNA) in maternal plasma or urine.
Detailed Description
This is an observational study whereby samples will be tested to determine the presence or absence of fetal Y chromosome genes to test for the fetal sex of the baby. The blood draw and urine collection will occur between 36-42, 43-49, and 50-56 days gestation. The fetal gender will be requested at or soon after delivery. The accuracy of the test and the optimal time to perform the test during pregnancy will be assessed by comparing the test results from maternal blood and/or urine samples obtained between days 36 and 56 of gestation to the fetal sex results obtained at birth.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject is 18-45 years of age inclusive
- •Subject is female
- •Subject is pregnant
- •Gestational age can be determined via IVF or IUI
- •Subject is 36-42 days pregnant as determined by IVF transfer or IUI
- •Subject agrees to provide 3 separate blood and urine samples
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Develop a prenatal sex test using blood and/or urine samples from pregnant women.
Time Frame: 36 to 56 days of gestation
Secondary Outcomes
- Establish the earliest time point between days 36 and 56 of gestation that the prenatal sex test has optimal performance.(36 to 56 days of gestation)